By Fineline Cube 
Gan & Lee Pharmaceuticals (SHA: 603087) announced a licensing agreement with JW Pharmaceutical, granting the South Korean firm exclusive development and commercialization rights to bonfaglutide, Gan & Lee’s in‑house developed long‑acting GLP‑1 receptor agonist, for type 2 diabetes (T2D) and weight management indications in South Korea.
Transaction Structure
| Component | Value | Detail |
|---|---|---|
| Upfront Payment | US$5 million | One‑time, non‑refundable |
| Milestone Payments | US$76.1 million | Tied to development, regulatory approvals, commercialization |
| Royalties | Tiered | On net sales post‑launch |
| Total Deal Value | US$81.1 million | Aggregate potential consideration |
Product Profile
- Molecule: Bonfaglutide – Long‑acting GLP‑1 receptor agonist
- Developer: Gan & Lee Pharmaceuticals (internal R&D)
- Indications: Type 2 diabetes (T2D) + weight management
- Mechanism: Enhances glucose‑dependent insulin secretion, suppresses glucagon, delays gastric emptying, reduces appetite
- Competitive Position: Positioned within the US$30 billion+ global GLP‑1 market dominated by Novo Nordisk and Eli Lilly
Strategic Expansion
| Region | Partner | Status |
|---|---|---|
| Latin America | Undisclosed | Active partnership |
| India | Undisclosed | Active partnership |
| South Korea | JW Pharmaceutical | New deal (Apr 2026) |
This marks Gan & Lee’s third out‑licensing transaction for bonfaglutide, demonstrating sustained international demand for its GLP‑1 asset.
Market Context & Outlook
- Korea GLP‑1 Market: South Korea represents a US$400 million+ annual market for GLP‑1 therapies, with obesity coverage expanding under national health insurance.
- JW Pharma Fit: Established Korean pharmaceutical company with proven metabolic disease commercialization infrastructure and endocrinology specialist network.
- Gan & Lee Strategy: Asset‑light international expansion via licensing preserves capital while capturing milestone and royalty upside; retains full rights for Greater China core market.
- Pipeline Validation: Repeated out‑licensing deals signal bonfaglutide’s competitive clinical profile; potential US/EU partnership could follow pending Phase III data readouts.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding milestone achievements, regulatory timelines, and commercial projections for bonfaglutide. Actual results may differ due to risks including clinical trial failures, regulatory rejections, competitive market entry, and partner performance.-Fineline Info & Tech